Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc. is a clinical-stage biotechnology company engaged in the development and commercialization of novel therapeutics to address infectious diseases, immunization and cardiovascular conditions. With a focus on gene therapy, vaccine candidates and antimicrobial agents, Oragenics leverages proprietary platforms to discover and advance biologically based solutions for unmet medical needs. The company’s research and development activities span from early-stage discovery through to clinical trials, positioning it at the forefront of translational biopharmaceutical innovation.

The company’s pipeline includes Generx®, a first-in-class DNA-based gene therapy candidate designed to promote angiogenesis in patients suffering from chronic refractory angina; P-301™, a recombinant quadrivalent influenza vaccine currently in preclinical development; and a suite of novel antimicrobial peptides engineered to target multi-drug resistant bacterial pathogens. Oragenics has also established partnerships and licensing agreements to explore additional applications of its platform technologies in targeted delivery and immune modulation.

Founded in 1997 and headquartered in Tampa, Florida, Oragenics has built a robust network of collaborations with academic research institutions, contract development and manufacturing organizations (CDMOs), and government agencies. The company’s work extends across North America and into select international markets through research collaborations aimed at accelerating the translation of laboratory discoveries into clinical candidates. Over the years, Oragenics has maintained a nimble footprint that enables rapid decision-making and adaptability in response to emerging health challenges.

Oragenics is led by President and Chief Executive Officer Raymond D. Hill, who brings extensive experience in biotech management and strategic partnerships, and Chief Scientific Officer Michael L. Rouse, Ph.D., whose background in molecular biology and gene therapy drives the company’s R&D efforts. Under their leadership, Oragenics seeks to advance its lead candidates through pivotal studies, secure additional collaborative arrangements and ultimately deliver new therapeutic options to patients worldwide.

Key Stats

• Today's Range: $1.32 to $1.47
• 50-Day Range: $1.42 to $6.06
• 52-Week Range: $1.32 to $75.60
• Volume: 315,467 shs
• Average Volume: 198,201 shs
• Market Capitalization: $1.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oragenics Stock Analysis - MarketRank™

Oragenics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oragenics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oragenics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oragenics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oragenics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

45.59% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oragenics does not currently pay a dividend.

Dividend Growth

Oragenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

45.59% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for OGEN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added Oragenics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oragenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.90% of the stock of Oragenics is held by insiders.

Percentage Held by Institutions

Only 18.71% of the stock of Oragenics is held by institutions.

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed this year?

Oragenics' stock was trading at $11.0790 at the beginning of 2025. Since then, OGEN shares have decreased by 87.2% and is now trading at $1.42.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) announced its quarterly earnings results on Monday, August, 16th. The company reported ($54.00) earnings per share for the quarter, topping the consensus estimate of ($72.00) by $18.00.

When did Oragenics' stock split?

Shares of Oragenics reverse split on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Animal Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 8/16/2021
• Today: 7/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGEN
• Previous Symbol: NYSE:OGEN
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($33.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.66 million
• Net Margins: N/A
• Pretax Margin: -243,950.00%
• Return on Equity: -2,087.95%
• Return on Assets: -486.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 823,000
• Free Float: 10,979,000
• Market Cap: $1.16 million
• Optionable: N/A
• Beta: 0.95